Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.54 |
| ▸ | SNCA | P37840 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.48 |
| ▸ | KDM5A | P29375 | 1/20 | 0.48 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27869431 | 0.87 | TSHR (0.53) | NR4A2KDM4CKDM5AKDM5BHCAR2 | |
| SCHEMBL19067568 | 0.85 | RXRA (0.47) | NR4A2SNCARXRAPTPN1TSHR | |
| SCHEMBL11820084 | 0.85 | NR4A2 (0.51) | NR4A2RXRAKDM4CKDM5AKDM5B | |
| SCHEMBL9937243 | 0.83 | MRGPRX4 (0.54) | NR4A2SNCAPTPN1 | |
| SCHEMBL9937934 | 0.82 | NR4A2 (0.63) | NR4A2KDM4CKDM5AKDM5BHCAR2 | |
| SCHEMBL9938831 | 0.81 | NR4A2 (0.63) | NR4A2RXRAKDM4CKDM5AKDM5B | |
| SCHEMBL27147458 | 0.79 | MRGPRX4 (0.62) | RXRAKDM4CKDM5AKDM5BPTPN1 | |
| SCHEMBL28117926 | 0.78 | TSHR (0.57) | NR4A2HCAR2PTPN1TSHR | |
| SCHEMBL28780702 | 0.78 | NR4A2 (0.55) | NR4A2KDM4CKDM5AKDM5BHCAR2 | |
| SCHEMBL11828345 | 0.78 | RXRA (0.53) | RXRAKDM4CKDM5AKDM5BTAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651888-B1 | N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders | UNIV LEUVEN KATH (BE) | 2017-05-17 | — | — | EP | disclosed |
| US-9266832-B2 | Compounds for the treatment of neurodegenerative diseases | Katholieke Universiteit Levun (BE) | 2016-02-23 | — | — | US | disclosed |
| EP-2651888-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-17 | — | — | US | disclosed |
| WO-2012080221-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, PSEN1 | NR4A2 3464/4885SNCA 1/4885RXRA 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.